NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter’s transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.
This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
William G. Wierda, MD, PhD, Panel Chair, has disclosed that he receives grant/research support from AbbVie, Inc.; Acerta Pharma, LLC; Cyclacel Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Intrexon Corporation; Juno Therapeutics, Inc.; Kite Pharma, Inc.; Oncternal Therapeutics; Precigen, Inc.; Xencor, Inc.; Pharmacyclics, Inc.; Roche Laboratories, Inc.; and Sunesis Pharmaceuticals, Inc. He also receives consulting fees/honoraria from sanofi-aventis U.S. LLC.
John C. Byrd, MD, Panel Vice Chair, has disclosed that he has no relevant financial relationships.
Jennifer Brown, MD, PhD, Panel Member, has disclosed that she receives grant/research support from Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Verastem Oncology, and Loxo Oncology; and that she serves on the data safety monitoring committee for Invectys. She also receives consulting fees/honoraria from AbbVie, Inc.; Acerta Pharma, LLC; BeiGene; Janssen Pharmaceuticals, Inc.; Juno Therapeutics, Inc.; Celgene Corporation; Kite Pharma, Inc.; Morphosys; Sunesis Pharmaceuticals, Inc.; Teva Pharmaceutical Industries, TG Therapeutics, Inc.; and Verastem Oncology.
Sami Malek, MD, Panel Member, has disclosed that he has equity interest/stock options in AbbVie, Inc., Gilead Sciences, Inc., and Portola Pharmaceuticals; and that he receives grant/research support from Janssen Pharmaceutica Products, LP, and Pharmacyclics, Inc.
Mazyar Shadman, MD, MPH, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc.; Acerta Pharma, LLC; BeiGene; Celgene Corporation; Emergent BioSolutions Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Mustang Bio, Inc.; TG Therapeutics, Inc.; and Pharmacyclics, Inc. He also serves as a scientific advisor for AbbVie, Inc.; Genentech, Inc.; ADC Therapeutics; Atara Biotherapeutics, Inc.; Sound Biologics; and Verastem Oncology.
Deborah Stephens, DO, Panel Member, has disclosed that she has no relevant financial relationships.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-19-004-H01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation